Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation

Clinical Infectious Diseases

Volumn 23, Issue 3, 1996, Pages 532-537

  Saiman, Lisa ^a   Mehar, Farrah ^b   Niu, Wei Wei ^b   Neu, Harold C ^b   Shaw, Karen J ^b   Miller, George ^b   Prince, Alice ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; IMIPENEM;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHRONIC LUNG DISEASE; CYSTIC FIBROSIS; FEMALE; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0029808250     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.3.532     Document Type: Article

References (14)

1. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-9.
2. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
3. Burns JL, Ramsey BW, Smith AL. Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis 1993;8:53-66.
4. Ogle JW, Reller LB, Vasil ML. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe. J Infect Dis 1988;157:743-8.
5. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med 1994;149:1601-7.
6. Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993;103:466-71.
7. Waitz JA, Doern GV, Finegold SM, et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Vol. 10. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1991.
8. Shimizu K, Kumada T, Hsieh W-C, et al. Comparison of aminoglycoside resistance patterns in Japan, Formosa, Korea, Chile and the United States. Antimicrob Agents Chemother 1985;28:282-8.
9. Shaw KJ, Hare RS, Sabatelli FJ, et al. Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates. Antimicrob Agents Chemother 1991;35:2253-61.
10. Elion GB, Singer S, Hitchings GH. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 1954;208:477-88.
11. Garrod LP, Waterworth PM. Methods of testing combined antibiotic bactericidal action and the significance of the results. J Clin Pathol 1962;15:328-38.
12. Shaw KJ, Cramer CA, Rizzo M, et al. Isolation, characterization, and DNA sequence analysis of an AAC(6′)-II gene from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1989;33:2052-62.
13. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. New Engl J Med 1993;328:1740-6.
14. Diver JM, SchoIIaardt T, Rabin HR, Thorson C, Bryan LE. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother 1991;35:1538-46.